Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6785-6795

  Smith, Heath A ^a   Cronk, Robert J ^a   Lang, Joshua M ^a   McNeel, Douglas G ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; DNA VACCINE; EPITOPE; HLA A2 ANTIGEN; PEPTIDE VACCINE; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 1; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 10; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 2; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 3; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 4; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 5; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 6; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 7; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 8; SYNOVIAL SARCOMA X CHROMOSOME BREAKPOINT PROTEIN 9; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; DRUG TARGETING; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CANCER VACCINES; CELL LINE, TUMOR; EPITOPES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-A2 ANTIGEN; HLA-DR1 ANTIGEN; HUMANS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; MULTIGENE FAMILY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 80155131086     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2127     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Vieweg J. Immunotherapy for advanced prostate cancer. Rev Urol 2007;9Suppl 1:S29-38.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
4. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94. (Pubitemid 46638945)
5. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105.
6. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004;91:688-94. (Pubitemid 39141625)
7. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009;27:4047-54.
8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
9. Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007;2:182-90. (Pubitemid 47554839)
10. Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 2011;29:1504-13.
11. Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006;119:2428-34. (Pubitemid 44546968)
12. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001;61:423-7. (Pubitemid 32128590)
13. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995;46:681-6; discussion 686-7.
14. Grob BM, Schellhammer PF, Brassil DN, Wright GL Jr. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer. Urology 1994;44:525-9.
15. Mhawech-Fauceglia P, Smiraglia DJ, Bshara W, Andrews C, Schwaller J, South S, et al. Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008;17:571-7. (Pubitemid 351469206)
16. Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007;17:275-87. (Pubitemid 47211962)
17. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100:2014-21.
18. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med 2009;12:395-404.
19. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003;194:272-88. (Pubitemid 36176890)
20. Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005;174:1709-16.
21. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancertestis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate 2007;67:1781-90. (Pubitemid 350228730)
22. Gnjatic S, Wheeler C, Ebner M, Ritter E, Murray A, Altorki NK, et al. Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods 2009;341:50-8.
23. Niemeyer P, Tureci O, Eberle T, Graf N, Pfreundschuh M, Sahin U. Expression of serologically identified tumor antigens in acute leukemias. Leuk Res 2003;27:655-60. (Pubitemid 36398102)
24. Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanovic S, et al. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigenspecific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 2003;9:4376-86. (Pubitemid 37248394)
25. Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000;60:4499-506. (Pubitemid 32103631)
26. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/ testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
27. Fijak M, Meinhardt A. The testis in immune privilege. Immunol Rev 2006;213:66-81. (Pubitemid 44401494)
28. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'Neill D, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 2007;7:11.
29. Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Driesch P, Schuler G, et al. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res 2005;296:314-9. (Pubitemid 40169524)
30. Gure AO, Tureci O, Sahin U, Tsang S, Scanlan MJ, Jager E, et al. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 1997;72:965-71. (Pubitemid 27433559)
31. Smith HA, McNeel DG. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol 2010:150591.
32. Taylor BJ, Reiman T, Pittman JA, Keats JJ, de Bruijn DR, Mant MJ, et al. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother 2005;28:564-75. (Pubitemid 41533090)
33. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005;65: 2207-15. (Pubitemid 40490129)
34. Tureci O, Chen YT, Sahin U, Gure AO, Zwick C, Villena C, et al. Expression of SSX genes in human tumors. Int J Cancer 1998;77: 19-23. (Pubitemid 28308546)
35. Gure AO, Wei IJ, Old LJ, Chen YT. The SSX gene family: characterization of 9 complete genes. Int J Cancer 2002;101:448-53.
36. Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother 2011;34:569-80.
37. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
38. Daud II, Scott ME. Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol 2008;15:1369-73.
39. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
40. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9. (Pubitemid 30099526)
41. Olson BM, McNeel DG. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother 2011;60: 781-92.
42. Pajot A, Michel ML, Fazilleau N, Pancre V, Auriault C, Ojcius DM, et al. A mouse model of human adaptive immune functions: HLA-A2.1-/ HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 2004;34:3060-9. (Pubitemid 39549385)
43. Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother 2010;59:943-53.
44. Tureci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ, et al. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 1996;56:4766-72. (Pubitemid 26338082)
45. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97:103-15. (Pubitemid 40277090)
46. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009;181: 1678-85.
47. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007;177: 822-31. (Pubitemid 46223571)
48. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res 2002; 12:996-1006. (Pubitemid 34662293)